Hibsago (bepirovirsen) is an FDA-approved medicine for adults with chronic hepatitis B (CHB). It is used along with existing hepatitis B medicines called nucleos(t)ide analogues. It is approved for eligible adults without cirrhosis who meet specific treatment and viral load requirements.
Hibsago works by targeting the virus’s RNA (genetic material), helping reduce its ability to multiply in the body. It is the first approved medicine that can help some people achieve a functional cure for chronic hepatitis B. A functional cure means the virus remains controlled even after treatment ends, although it may still be present in the body. Discovered and developed by Ionis Pharmaceuticals and marketed by GSK, Hibsago marks an important development in chronic hepatitis B treatment.